Everolimus



Indications and Reactions:

Role Indications Reactions
Primary
Liver Transplant 19.7%
Renal Transplant 18.5%
Heart Transplant 8.0%
Metastatic Renal Cell Carcinoma 7.1%
Hypertension 5.2%
Breast Cancer Metastatic 4.8%
Prophylaxis 4.7%
Acute Myeloid Leukaemia 4.5%
Renal Cell Carcinoma 4.2%
Immunosuppression 3.6%
Renal Cancer Metastatic 3.0%
Hepatic Neoplasm Malignant 2.7%
Breast Cancer 2.7%
Diabetes Mellitus 2.2%
Tuberous Sclerosis 2.1%
Gastric Cancer 1.8%
Pancreatic Neuroendocrine Tumour 1.7%
Thyroid Cancer 1.1%
Asthma 1.1%
Off Label Use 1.1%
Death 12.5%
Pyrexia 8.8%
Vomiting 8.8%
Neoplasm Malignant 6.1%
Concomitant Disease Progression 5.7%
Respiratory Failure 5.4%
Thrombocytopenia 5.1%
Dyspnoea 4.7%
General Physical Health Deterioration 4.7%
Anaemia 4.0%
Pneumonia 4.0%
Neoplasm Progression 3.7%
Oedema Peripheral 3.7%
Diarrhoea 3.4%
Erysipelas 3.4%
Febrile Neutropenia 3.4%
Pleural Effusion 3.4%
Stomatitis 3.4%
Interstitial Lung Disease 3.0%
Pulmonary Embolism 3.0%
Secondary
Renal Transplant 20.4%
Drug Use For Unknown Indication 10.0%
Heart Transplant 9.7%
Immunosuppression 7.0%
Product Used For Unknown Indication 6.7%
Liver Transplant 6.0%
Hypertension 5.6%
Transplant Rejection 5.2%
Breast Cancer 4.0%
Metastatic Renal Cell Carcinoma 3.8%
Prophylaxis Against Transplant Rejection 3.8%
Prophylaxis 3.7%
Glioblastoma Multiforme 2.7%
Renal Cell Carcinoma 2.5%
Immunosuppressant Drug Therapy 1.6%
Breast Cancer Metastatic 1.6%
Neuroendocrine Tumour 1.5%
Pancreatic Neuroendocrine Tumour 1.5%
Hepatic Neoplasm Malignant 1.4%
Gastric Cancer 1.4%
Transplant Rejection 12.1%
Vomiting 10.8%
Troponin I Increased 7.3%
Pyrexia 6.7%
Thrombocytopenia 6.3%
Interstitial Lung Disease 5.4%
Proteinuria 4.4%
Pulmonary Embolism 4.4%
Renal Failure Acute 4.1%
Rash 3.8%
Renal Impairment 3.8%
Sepsis 3.8%
Thrombotic Microangiopathy 3.8%
Neutropenia 3.5%
Septic Shock 3.5%
Urinary Tract Infection 3.5%
Diarrhoea 3.2%
Febrile Neutropenia 3.2%
Pneumonia 3.2%
Stomatitis 3.2%
Concomitant
Product Used For Unknown Indication 21.0%
Renal Transplant 14.9%
Immunosuppression 12.6%
Heart Transplant 8.9%
Hypertension 5.4%
Immunosuppressant Drug Therapy 4.5%
Prophylaxis Against Transplant Rejection 4.4%
Coronary Artery Disease 4.1%
Drug Use For Unknown Indication 4.0%
Prophylaxis 2.9%
Breast Cancer Metastatic 2.5%
Glioblastoma Multiforme 2.0%
Pain 2.0%
Renal Cell Carcinoma 2.0%
Pancreatic Neuroendocrine Tumour 1.9%
Hepatitis C 1.6%
Colorectal Cancer 1.5%
Breast Cancer 1.3%
Dyslipidaemia 1.3%
Heart And Lung Transplant 1.3%
Renal Impairment 14.3%
Renal Failure Acute 8.2%
Death 7.1%
Pneumonitis 5.1%
Rash 5.1%
Renal Failure 5.1%
Thrombocytopenia 5.1%
Tubulointerstitial Nephritis 5.1%
Disease Progression 4.1%
Drug Interaction 4.1%
Hepatocellular Carcinoma 4.1%
Hypocalcaemia 4.1%
Osteonecrosis Of Jaw 4.1%
Pancytopenia 4.1%
Renal Atrophy 4.1%
Swelling Face 4.1%
Blood Creatinine Increased 3.1%
Enterovesical Fistula 3.1%
Face Oedema 3.1%
Fatigue 3.1%
Interacting
Immunosuppression 22.3%
Product Used For Unknown Indication 16.8%
Drug Use For Unknown Indication 8.4%
Pulmonary Tuberculosis 7.3%
Hypertension 5.6%
Infection Prophylaxis 5.0%
Tuberculosis 5.0%
Antifungal Prophylaxis 3.4%
Candida Pneumonia 3.4%
Liver Carcinoma 3.4%
Pneumonia Bacterial 3.4%
Liver Transplant 2.2%
Lung Transplant 2.2%
Prophylaxis Against Transplant Rejection 2.2%
Back Pain 1.7%
Erysipelas 1.7%
Hypercholesterolaemia 1.7%
Pain 1.7%
Renal Transplant 1.7%
Blood Pressure 1.1%
Pneumonia 15.2%
Renal Failure Acute 15.2%
Drug Interaction 12.1%
Hepatotoxicity 9.1%
Renal Tubular Atrophy 9.1%
Staphylococcal Infection 6.1%
Subdural Haemorrhage 6.1%
Vomiting 6.1%
Angioedema 3.0%
Enteritis 3.0%
Haemoglobin Decreased 3.0%
Lip Swelling 3.0%
Oedema Peripheral 3.0%
Renal Failure 3.0%
Transaminases Increased 3.0%